Filing Details

Accession Number:
0001628280-24-010750
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-12 21:44:41
Reporting Period:
2024-03-08
Accepted Time:
2024-03-12 21:44:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
834365 Biolife Solutions Inc BLFS Electromedical & Electrotherapeutic Apparatus (3845) 943076866
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1633186 Todd Berard 3303 Monte Villa Parkway
Suite 310
Bothell WA 98021
Chief Marketing Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-08 14,456 $0.00 130,144 No 4 A Direct
Common Stock Acquisiton 2024-03-08 17,523 $0.00 147,667 No 4 A Direct
Common Stock Disposition 2024-03-11 401 $17.42 147,266 No 4 S Direct
Common Stock Disposition 2024-03-12 7,107 $16.60 140,159 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 A Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2024 compensation.
  2. The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 125% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
  3. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.